Tivic Health Validates European Patents

Tivic Health Systems Inc. has validated two granted European Patent Office (EPO) patents in Great Britain, Germany, and France—validations the company contends are an important step toward securing the foundation for an international market position.

The newly validated patents in Great Britain, Germany and France:

• European Patent EP3615133, both titled, “Adaptive Trigger For a Microcurrent Stimulation Device,” protects device and methods the company uses to identify preferred treatment points and trigger the treatment mode of its sinus treatment device. Triggers can be programmed in various ways to improve consumer performance and ease of use.
• European Patent EP3615134, “Sinus Treatment Device With Adaptive Circuit,” protects the device and methods the company uses to dynamically adjust stimulation voltage applied during a treatment phase, allowing for dynamic treatment personalization. The dynamic changes in stimulation voltage help to maximize comfort, enhance device performance, and enrich user experience.

“Validation of these key patents in Europe further strengthens our patent position for ClearUP,” Tivic Health Chief Scientific Officer Blake Gurfein said. “These patents are part of an international portfolio that includes 16 issued patents and 10 pending patents spanning the U.S., Europe, India, and China.”

Tivic Health is a commercial health tech company advancing bioelectronic medicine. Its patented technology platform leverages stimulation on the trigeminal, sympathetic, and vagus nerve structures. Tivic Health’s non-invasive and targeted approach to treating inflammatory chronic health conditions gives consumers and providers drug-free therapeutic solutions with high safety profiles, low risk, and broad applications. Tivic Health’s first commercial product, ClearUP, is a U.S. Food and Drug Administration approved, award-winning, handheld bioelectronic sinus device.